Amgen Inc. (NASDAQ:AMGN)’s thrombocytopenia drug Nplate (romiplostim) showed significant benefits in a Phase III trial for ...

Nplate improved platelet response and reduced therapy modification for patients with chemotherapy-induced thrombocytopaenia.

Community oncology faces significant challenges from the Inflation Reduction Act's (IRA) drug pricing changes, risking ...

Amgen's Nplate proves highly effective in preventing thrombocytopenia from chemotherapy, enabling full-dose cancer treatment ...

Amgen's Nplate, which treats low blood platelet counts caused by an autoimmune condition, was highly effective at preventing ...

Explore growth drivers, innovations, and future trends shaping the Thrombocytopenia Treatment Market from 2025 to 2035 Thrombocytopenia treatment market to witness transformative growth driven by ...

Associations between acupuncture and uses of opioids and neuropsychiatric medication following chemotherapy-induced peripheral neuropathy among patients with breast cancer. Pool analysis of Part A ...